A Phase 3 interventional study of Naproxen Sodium ER (BAYH6689) and Naproxen Sodium IR (Aleve, BAYH6689) in Pain, Postoperative, sponsored by Bayer. Completed at 1 site in United States. Open to participants aged 15 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-08-25.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing naproxen in Pain, Postoperative — 2 open to participants now, 2 under way, 1 of them phase 3. Naproxen · Pain, Postoperative.
Among the 13 studies testing naproxen in Pain, Postoperative, this one is the 5th largest by enrollment, is one of 2 that started in 2011, is one of 5 in phase 3, and was the 3rd registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,240 are open to participants now.
Browse Pain, Postoperative studies →2 of the 13 studies testing naproxen in Pain, Postoperative are open now, in 1 country. Recruiting first, the newest first:
Rothman Institute Orthopaedics · Sites in United States
Ages 18+ · Healthy volunteers
Rothman Institute Orthopaedics · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Naproxen: first FDA approval 1976 (NAPROSYN). What it is approved for, and how studies give it, is on its page →
Of the 675 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 328 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 15 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 6 · Phase 4 4
First in 2008; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 300 is above the median of 75 across 4,854 interventional studies indexed under Pain, Postoperative.
Median enrollment 200 across the 13 interventional studies. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 13 have an industry lead sponsor. The 7 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.
Bayer has 5 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing naproxen in Pain, Postoperative, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective is to evaluate pain relief of the extended release naproxen sodium 660 mg tablet compared to commercial naproxen sodium 220 mg tablet over 24 hours in patients with postsurgical dental pain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 naproxen sodium extended release (ER) 660 mg tablet and 1 naproxen sodium immediate release (IR) 220 mg placebo tablet initially followed by 1 naproxen sodium IR 220 mg matching placebo tablet at hour 8 (± 15 min), and 1 naproxen sodium IR 220 mg matching placebo tablet at hour 16 (± 15 min)
Drug: Naproxen Sodium ER (BAYH6689) · Drug: Naproxen Sodium IR Placebo
1 naproxen sodium ER 660 mg matching placebo tablet and 1 naproxen sodium IR 220 mg tablet initially followed by 1 naproxen sodium IR 220 mg tablet at hour 8 (± 15 min), and 1 naproxen sodium IR 220 mg tablet eight hours at hour 16 (± 15 min)
Drug: Naproxen Sodium IR (Aleve, BAYH6689) · Drug: Naproxen Sodium ER Placebo
1 naproxen sodium ER 660 mg matching placebo tablet and 1 naproxen sodium IR 220 mg matching placebo tablet initially followed by 1 naproxen sodium IR 220 mg matching placebo tablet at hour 8 (± 15 min), and 1 naproxen sodium IR 220 mg matching placebo tablet at hour 16 (± 15 min)
Drug: Naproxen Sodium ER Placebo · Drug: Naproxen Sodium IR Placebo
660 mg Naproxen Sodium extended release tablet, orally administered once daily for 24 hours
220 mg Naproxen Sodium instant release tablet, orally administered 3 times daily (TID) for 24 hours
Matching placebo of 660 mg Naproxen Sodium ER for 24 hours
Matching placebo of 220 mg Naproxen Sodium IR (Aleve) for 24 hours
Summed, Time-weighted Pain Intensity Difference From 0 to 24 Hours Postdose (SPID0-24)
SPID0-24 was calculated by multiplying the pain intensity difference score at each post-dose timepoint by the duration (in hours) since the preceding timepoint and then summing these values over 0 to 24 hours. Pain intensity was measured at baseline, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, 12, 16, 20 and 24 hours using the 4-point categorical pain intensity scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe. SPID0-24 can vary from -24 to 72. The positive SPID value indicates improvement of pain relief. The higher the SPID value, the more improvement of pain relief.
Time frame: From 0 to 24 hours post-dose
Summed, Time-weighted Pain Intensity Differences (SPID)
Pain intensity was measured at baseline, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, 12, 16, 20 and 24 hours using the 4-point categorical pain intensity scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe. The total possible score ranges of SPIDs are SPID0-6: -6 to 18, SPID0-8: -8 to 24, SPID0-12: -12 to 36, SPID0-16: -16 to 48, SPID16-24: -8 to 24. The positive SPID value indicates improvement of pain relief. The higher the SPID value, the more improvement of pain relief.
Time frame: 0-6, 0-8, 0-12, 0-16 and 16-24 hours postdose
Summed, Time-weighted Total Pain Relief Scores (TOTPARs)
TOTPARs were derived by multiplying the pain relief score at each post-dose timepoint by the duration (in hours) since the preceding timepoint and then summing these values over the specified interval. Pain Relief was evaluated at 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, 12, 16, 20 and 24 hours postdose, using the 5-point overall pain relief scale: 0 = No relief, 1 = A little relief, 2 = Some relief, 3 = A lot of relief, 4 = Complete relief. The possible total score ranges of TOTPARs are: TOTPAR0-6: 0 to 18, TOTPAR0-8: 0 to 24, TOTPAR0-12: 0 to 36, TOTPAR0-16: 0 to 48, TOTPAR0-24: 0 to 72, TOTPAR16-24: 0 to 24.
Time frame: 0-6, 0-8, 0-12, 0-16, 0-24, and 16-24 hours postdose
Pain Intensity Differences (PIDs) by Time From Initial Dose
Pain intensity was evaluated using a 4-point Categorical Pain Intensity Rating Scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe
Time frame: At 0, 0.25, 0.5, 0.75, 1, 2, 3, 4 ,5 ,6, 8, 12, 16, 20 and 24 hours postdose
Pain Relief From Initial Dose
Pain Relief was evaluated using the 5-point overall pain relief scale: 0 = No relief, 1 = A little relief, 2 = Some relief, 3 = A lot of relief, 4 = Complete relief
Time frame: At 0.25, 0.5, 0.75, 1, 2, 3, 4 ,5 ,6, 8, 12, 16, 20 and 24 hours postdose
Median Time to First Intake of Rescue Medication
Time to first use of rescue medication was estimated using Kaplan-Meier method and analyzed by a logrank test stratified by baseline pain intensity. If at least 50% of subjects in a treatment group took rescue medication, the median time to first rescue was determined for that treatment group.
Time frame: Up to 24 hours postdose
Cumulative Percentage of Participants Who Took Rescue Medication
Time frame: At 0.25, 0.5, 0.75, 1, 2, 3, 4 ,5 ,6, 8, 12, 16, 20 and 24 hours postdose
Number of Times the Participants Took Rescue Medication Over the 24-hour Period
Time frame: 24 hours postdose
Global Assessment of the Investigational Product as a Pain Reliever
Global assessment of investigational product as a pain reliever was rated on a 5-point categorical scale: 0 = poor, 1 = fair, 2 = good, 3 = very good, 4 = excellent
Time frame: 24 hours postdose or immediately before the first intake of rescue medication
| Milestone | Naproxen Sodium ER (BAYH6689) | Naproxen Sodium IR (Aleve, BAYH6689) | Placebo |
|---|---|---|---|
| Started | 120 | 120 | 60 |
| Completed | 120 | 120 | 60 |
| Not completed | 0 | 0 | 0 |
SPID0-24 was calculated by multiplying the pain intensity difference score at each post-dose timepoint by the duration (in hours) since the preceding timepoint and then summing these values over 0 to 24 hours. Pain intensity was measured at baseline, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, 12, 16, 20 and 24 hours using the 4-point categorical pain intensity scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe. SPID0-24 can vary from -24 to 72. The positive SPID value indicates improvement of pain relief. The higher the SPID value, the more improvement of pain relief.
| Score on the scale | Naproxen Sodium ER (BAYH6689) | Naproxen Sodium IR (Aleve, BAYH6689) | Placebo |
|---|---|---|---|
| Summed, Time-weighted Pain Intensity Difference From 0 to 24 Hours Postdose (SPID0-24) | 23.2 ± 2.01 | 23.6 ± 2.01 | -0.6 ± 2.85 |
Pain intensity was measured at baseline, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, 12, 16, 20 and 24 hours using the 4-point categorical pain intensity scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe. The total possible score ranges of SPIDs are SPID0-6: -6 to 18, SPID0-8: -8 to 24, SPID0-12: -12 to 36, SPID0-16: -16 to 48, SPID16-24: -8 to 24. The positive SPID value indicates improvement of pain relief. The higher the SPID value, the more improvement of pain relief.
| Score on the scale | Naproxen Sodium ER (BAYH6689) | Naproxen Sodium IR (Aleve, BAYH6689) | Placebo |
|---|---|---|---|
| From 0 to 6 hours, LS Mean | 5.3 (4.5 to 6.7) | 5.3 (4.5 to 6.1) | -0.5 (-1.6 to 0.7) |
| From 0 to 8 hours, LS Mean | 7.0 (5.9 to 8.1) | 6.9 (5.7 to 8.0) | -0.8 (-2.3 to 0.8) |
| From 0 to 12 hours, LS Mean | 10.9 (9.1 to 12.7) | 10.9 (9.2 to 12.7) | -0.9 (-3.4 to 1.6) |
| From 0 to 16 hours, LS Mean | 14.7 (12.3 to 17.2) | 15.0 (12.5 to 17.5) | -1.0 (-4.5 to 2.6) |
| From 16 to 24 hours, LS Mean | 8.5 (6.9 to 10.0) | 8.6 (7.1 to 10.1) | 0.4 (-1.8 to 2.6) |
TOTPARs were derived by multiplying the pain relief score at each post-dose timepoint by the duration (in hours) since the preceding timepoint and then summing these values over the specified interval. Pain Relief was evaluated at 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, 12, 16, 20 and 24 hours postdose, using the 5-point overall pain relief scale: 0 = No relief, 1 = A little relief, 2 = Some relief, 3 = A lot of relief, 4 = Complete relief. The possible total score ranges of TOTPARs are: TOTPAR0-6: 0 to 18, TOTPAR0-8: 0 to 24, TOTPAR0-12: 0 to 36, TOTPAR0-16: 0 to 48, TOTPAR0-24: 0 to 72, TOTPAR16-24: 0 to 24.
| Score on the scale | Naproxen Sodium ER (BAYH6689) | Naproxen Sodium IR (Aleve, BAYH6689) | Placebo |
|---|---|---|---|
| From 0 to 6 hours | 13.1 (11.9 to 14.3) | 12.8 (11.6 to 14.0) | 4.7 (2.9 to 6.4) |
| From 0 to 8 hours | 17.4 (15.7 to 19.1) | 16.8 (15.1 to 18.5) | 6.1 (3.8 to 8.5) |
| From 0 to 12 hours | 26.5 (23.9 to 29.2) | 26.4 (23.7 to 29.0) | 9.7 (5.9 to 13.5) |
| From 0 to 16 hours | 35.5 (31.8 to 39.2) | 35.8 (32.0 to 39.5) | 13.4 (8.1 to 18.6) |
| From 0 to 24 hours | 54.5 (48.6 to 60.4) | 55.1 (49.2 to 61.0) | 21.8 (13.4 to 30.2) |
| From 16 to 24 hours | 19.0 (16.7 to 21.3) | 19.4 (17.1 to 21.6) | 8.4 (5.2 to 11.6) |
Pain intensity was evaluated using a 4-point Categorical Pain Intensity Rating Scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe
| Score on the scale | Naproxen Sodium ER (BAYH6689) | Naproxen Sodium IR (Aleve, BAYH6689) | Placebo |
|---|---|---|---|
| 0.25 hours, LS Mean | 1.9 (1.8 to 2.0) | 2.0 (1.9 to 2.1) | 2.0 (1.9 to 2.2) |
| 0.5 hours, LS Mean | 1.7 (1.6 to 1.8) | 1.7 (1.6 to 1.8) | 1.9 (1.8 to 2.1) |
| 0.75 hours, LS Mean | 1.4 (1.3 to 1.6) | 1.5 (1.4 to 1.6) | 2.0 (1.8 to 2.2) |
| 1 hours, LS Mean | 1.2 (1.1 to 1.4) | 1.4 (1.3 to 1.5) | 2.1 (1.9 to 2.3) |
| 2 hours, LS Mean | 1.2 (1.1 to 1.4) | 1.2 (1.0 to 1.3) | 2.3 (2.1 to 2.5) |
| 3 hours, LS Mean | 1.2 (1.1 to 1.4) | 1.2 (1.0 to 1.3) | 2.3 (2.1 to 2.6) |
| 4 hours, LS Mean | 1.2 (1.0 to 1.3) | 1.2 (1.1 to 1.4) | 2.3 (2.1 to 2.5) |
| 5 hours, LS Mean | 1.3 (1.1 to 1.4) | 1.2 (1.1 to 1.4) | 2.3 (2.1 to 2.5) |
| 6 hours, LS Mean | 1.3 (1.1 to 1.4) | 1.3 (1.1 to 1.4) | 2.3 (2.1 to 2.5) |
| 8 hours, LS Mean | 1.3 (1.2 to 1.5) | 1.4 (1.2 to 1.6) | 2.3 (2.1 to 2.6) |
| 12 hours, LS Mean | 1.2 (1.0 to 1.4) | 1.2 (1.0 to 1.3) | 2.2 (2.0 to 2.5) |
| 16 hours, LS Mean | 1.2 (1.0 to 1.4) | 1.2 (1.0 to 1.4) | 2.2 (1.9 to 2.5) |
| 20 hours, LS Mean | 1.2 (1.0 to 1.4) | 1.1 (1.0 to 1.3) | 2.2 (1.9 to 2.5) |
| 24 hours, LS Mean | 1.1 (0.9 to 1.3) | 1.1 (0.9 to 1.3) | 2.1 (1.8 to 2.3) |
Pain Relief was evaluated using the 5-point overall pain relief scale: 0 = No relief, 1 = A little relief, 2 = Some relief, 3 = A lot of relief, 4 = Complete relief
| Score on the scale | Naproxen Sodium ER (BAYH6689) | Naproxen Sodium IR (Aleve, BAYH6689) | Placebo |
|---|---|---|---|
| 0.25 hours | 0.9 ± 0.96 | 0.8 ± 0.92 | 0.6 ± 0.75 |
| 0.5 hours | 1.5 ± 1.08 | 1.3 ± 1.02 | 0.8 ± 0.94 |
| 0.75 hours | 2.0 ± 1.21 | 1.7 ± 1.14 | 0.9 ± 0.96 |
| 1 hour | 2.2 ± 1.29 | 2.0 ± 1.17 | 0.9 ± 1.02 |
| 2 hours | 2.3 ± 1.30 | 2.3 ± 1.29 | 0.8 ± 1.02 |
| 3 hours | 2.3 ± 1.33 | 2.4 ± 1.39 | 0.7 ± 1.03 |
| 4 hours | 2.4 ± 1.41 | 2.2 ± 1.43 | 0.9 ± 1.20 |
| 5 hours | 2.3 ± 1.35 | 2.2 ± 1.49 | 0.9 ± 1.23 |
| 6 hours | 2.2 ± 1.37 | 2.2 ± 1.53 | 0.8 ± 1.28 |
| 8 hours | 2.1 ± 1.40 | 2.0 ± 1.50 | 0.8 ± 1.23 |
| 12 hours | 2.3 ± 1.51 | 2.4 ± 1.57 | 0.9 ± 1.46 |
| 16 hours | 2.2 ± 1.52 | 2.3 ± 1.61 | 1.0 ± 1.47 |
| 20 hours | 2.3 ± 1.58 | 2.3 ± 1.63 | 1.0 ± 1.50 |
| 24 hours | 2.4 ± 1.63 | 2.5 ± 1.68 | 1.2 ± 1.73 |
Time to first use of rescue medication was estimated using Kaplan-Meier method and analyzed by a logrank test stratified by baseline pain intensity. If at least 50% of subjects in a treatment group took rescue medication, the median time to first rescue was determined for that treatment group.
| Hours | Naproxen Sodium ER (BAYH6689) | Naproxen Sodium IR (Aleve, BAYH6689) | Placebo |
|---|---|---|---|
| Median Time to First Intake of Rescue Medication | NA (NA to NA) | NA (NA to NA) | 2.9 (1 to 12) |
| Percentage of participants | Naproxen Sodium ER (BAYH6689) | Naproxen Sodium IR (Aleve, BAYH6689) | Placebo |
|---|---|---|---|
| 0.25 hours | 0 | 0 | 0 |
| 0.5 hours | 0.0 | 0.0 | 0.0 |
| 0.75 hours | 0.0 | 0.0 | 0.0 |
| 1 hour | 0.0 | 0.0 | 0.0 |
| 2 hours | 7.5 | 7.5 | 30.0 |
| 3 hours | 12.5 | 13.3 | 50.0 |
| 4 hours | 16.7 | 16.7 | 55.0 |
| 5 hours | 18.3 | 20.0 | 58.3 |
| 6 hours | 20.0 | 23.3 | 60.0 |
| 8 hours | 20.8 | 25.0 | 63.3 |
| 12 hours | 22.5 | 25.8 | 66.7 |
| 16 hours | 25.0 | 27.5 | 66.7 |
| 20 hours | 26.7 | 27.5 | 66.7 |
| 24 hours | 26.7 | 27.5 | 66.7 |
| Rescue medication intakes | Naproxen Sodium ER (BAYH6689) | Naproxen Sodium IR (Aleve, BAYH6689) | Placebo |
|---|---|---|---|
| Number of Times the Participants Took Rescue Medication Over the 24-hour Period | 0.5 ± 0.86 | 0.6 ± 1.02 | 1.4 ± 1.20 |
Global assessment of investigational product as a pain reliever was rated on a 5-point categorical scale: 0 = poor, 1 = fair, 2 = good, 3 = very good, 4 = excellent
| Participants | Naproxen Sodium ER (BAYH6689) | Naproxen Sodium IR (Aleve, BAYH6689) | Placebo |
|---|---|---|---|
| 0 - Poor | 16 | 18 | 34 |
| 1 - Fair | 14 | 12 | 5 |
| 2 - Good | 22 | 20 | 5 |
| 3 - Very good | 33 | 43 | 12 |
| 4 - Excellent | 35 | 27 | 4 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Naproxen Sodium ER (BAYH6689) | — | 0/120 (0%) | 28/120 (23.3%) |
| Naproxen Sodium IR (Aleve, BAYH6689) | — | 0/120 (0%) | 36/120 (30%) |
| Placebo | — | 0/60 (0%) | 23/60 (38.3%) |
| Event | Naproxen Sodium ER (BAYH6689) | Naproxen Sodium IR (Aleve, BAYH6689) | Placebo |
|---|---|---|---|
| HeadacheNervous system disorders | 11/120 | 14/120 | 12/60 |
| NauseaGastrointestinal disorders | 10/120 | 9/120 | 8/60 |
| DizzinessNervous system disorders | 2/120 | 6/120 | 2/60 |
| HypoaesthesiaNervous system disorders | 2/120 | 4/120 | 3/60 |
| VomitingGastrointestinal disorders | 4/120 | 3/120 | 2/60 |
| AlveolitisRespiratory, thoracic and mediastinal disorders | 1/120 | 3/120 | 2/60 |
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 1/120 | 1/120 | 2/60 |
| Ear painEar and labyrinth disorders | 1/120 | 2/120 | 0/60 |
| Paraesthesia oralGastrointestinal disorders | 0/120 | 0/120 | 1/60 |
| Feeling hotGeneral disorders | 0/120 | 2/120 | 0/60 |
| Age, Continuous(Years) | Naproxen Sodium ER (BAYH6689) | Naproxen Sodium IR (Aleve, BAYH6689) | Placebo | Total |
|---|---|---|---|---|
| Mean | 24.0 ± 5.05 | 23.0 ± 4.67 | 25.0 ± 6.56 | 23.8 ± 5.28 |
| Sex: Female, Male(Participants) | Naproxen Sodium ER (BAYH6689) | Naproxen Sodium IR (Aleve, BAYH6689) | Placebo | Total |
|---|---|---|---|---|
| Female | 70 | 71 | 41 | 182 |
| Male | 50 | 49 | 19 | 118 |
| Pain Intensity Score(Participants) | Naproxen Sodium ER (BAYH6689) | Naproxen Sodium IR (Aleve, BAYH6689) | Placebo | Total |
|---|---|---|---|---|
| 0 = None | 0 | 0 | 0 | 0 |
| 1 = Mild | 0 | 0 | 0 | 0 |
| 2 = Moderate | 96 | 97 | 53 | 246 |
| 3 = Severe | 24 | 23 | 7 | 54 |
The record gives a start of Jun 2011, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.
Results were first posted in May 2013, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Naproxen